Lipid metabolism pathway modulation

"Lipid metabolism pathway modulation" is not a specific molecule, receptor, or protein but rather refers to the broad therapeutic strategy of altering one or more biochemical pathways involved in lipid metabolism. This includes targeting enzymes, transporters, receptors, and transcription factors that regulate the synthesis, breakdown, uptake, and storage of lipids such as fatty acids, cholesterol, triglycerides, and phospholipids[8][9]. Modulation of these pathways has been investigated as a means to treat diseases like cancer[1][5][7], neurodegenerative disorders such as Alzheimer's disease[3], cardiovascular diseases[9], and metabolic syndromes.\n\nKey molecular targets within lipid metabolism include:\n- **Enzymes:** e.g., fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), HMG-CoA reductase\n- **Transporters:** e.g., CD36/fatty acid translocase[2], fatty acid transport proteins (FATPs)[4]\n- **Receptors:** e.g., peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs)[3][8]\n- **Transcription factors:** e.g., sterol regulatory element-binding proteins (SREBPs)[8]\n\nTherapeutic agents may act by inhibiting or activating these components. For example:\n- Statins inhibit HMG-CoA reductase to lower cholesterol.\n- PPAR agonists modulate lipid storage and glucose homeostasis.\n- Experimental inhibitors target FASN or CD36 in cancer therapy.\n\nBecause this entry does not refer to a single defined molecular entity but rather an entire class of biological processes and potential drug targets within those processes, it is not considered a canonical therapeutic target itself; instead it encompasses many possible targets with diverse mechanisms of action depending on the context.[1][3][5]\n\nSummary judgment: The term “lipid metabolism pathway modulation” is too broad and non-specific to serve as a canonical name for any single molecule/receptor/target. It should be replaced with specific protein/gene names when structuring data about drug targets.